Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dato-DXd in TNBC Patients With Newly Diagnosed or Progressing Brain Metastases
2024-518819-19-00Phase 2Authorised
- Sponsor
- Medical University of Vienna
- Start
- May 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of datopotamab deruxtecan in triple-negative breast cancer (TNBC), breast cancer and Carcinomatous Meningitis (CM), sponsored by Medical University of Vienna. Primary endpoint: Intracranial response rate. Planned start May 2023; status: authorised.
02
Drugs
datopotamab deruxtecan
03
Conditions
triple-negative breast cancer (TNBC)breast cancerCarcinomatous Meningitis (CM)
Beyond the preview
Go deeper on 2024-518819-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518819-19-00.